Preliminary clinical experience of PCSK9 inhibitors in patients with heterozygous familial hypercholesterolemia. Considerations on their use in patients on lipoprotein apheresis treatment and in statins intolerant patients

The introduction of monoclonal antibodies anti-PCSK9 as a treatment option in patients with Heterozygous Familial Hypercholesterolemia (HeFH) represents a recent advancement in the pharmacological toolbox currently available to reach the recommended individual LDL-cholesterol (LDL-C) target.

http://www.nmcd-journal.com/article/S0939-4753(16)30204-6/fulltext?rss=yes

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - December 31, 2016 Category: Nutrition Authors: A. Altomari, V. Sanga, G. Ceradini, A. Fabris, A. Lupo, E. Bonora, M. Dauriz, M.G. Zenti Source Type: research